Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results

Sutro Biopharma ( (STRO) ) has released its Q2 earnings. Here is a breakdown of the information Sutro Biopharma presented to its investors.

Sutro Biopharma, Inc. is a biotechnology company specializing in the development of innovative cancer therapeutics, particularly focusing on antibody drug conjugates (ADCs) with a unique site-specific approach.

In its second quarter of 2025 earnings report, Sutro Biopharma highlighted significant advancements in its ADC pipeline, including preparations for a clinical trial of STRO-004 and a new collaboration with the FDA to enhance regulatory standards for ADCs. The company also announced the appointment of Greg Chow as Chief Financial Officer and reported a cash position of $205.1 million, providing a runway into early 2027.

Key financial metrics from the quarter showed a revenue increase to $63.7 million, primarily driven by collaborations, notably with Astellas, which triggered a $7.5 million milestone payment. Despite a net loss of $11.5 million, the company reduced its R&D and G&A expenses significantly compared to the previous year. Sutro also continues to focus on its dual-payload ADCs, which have shown promising preclinical results and are expected to enter clinical development in the coming years.

Strategically, Sutro is advancing its wholly-owned pipeline with plans to initiate a first-in-human trial for STRO-004 in the second half of 2025 and to enter clinical development for STRO-006 in 2026. The company is also progressing its dual-payload ADC platform with an anticipated IND filing in 2027.

Looking forward, Sutro Biopharma remains committed to executing its pipeline priorities to enhance shareholder value, while exploring operational efficiencies to extend its cash runway. The company’s innovative approach and strategic collaborations position it well for future growth in the oncology therapeutics market.